Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 89954. Отображено 100.
05-01-2012 дата публикации

Biologically active food supplement

Номер: US20120003200A1
Принадлежит: Individual

A biologically active food supplement intended to increase the athletes' muscle mass comprises Leuzea (or other medicinal plant containing ecdysteroids), male bee brood, ascorbic acid (Vitamin C), Vitamin E, and excipients (calcium stearate, talc, lactose) with the following ratio of components (mass %): Male bee brood 1-70; Leuzea 5-70; Ascorbic acid 1-70; Vitamin E 0.05-30; calcium stearate 0.92-0.95, talc 3-6, lactose—the rest.

Подробнее
05-01-2012 дата публикации

Premix emulsion

Номер: US20120003357A1
Принадлежит: DSM IP ASSETS BV

Sterile oil-in-water emulsion containing a water phase, one or more water soluble ingredient(s) and one or more emulsifiers selected from the group of caseinates.

Подробнее
05-01-2012 дата публикации

Nutritional composition for infants

Номер: US20120004163A1
Принадлежит: Nestec SA

A nutritional composition for infants comprises a protein source, a lipid source and a carbohydrate source wherein the lipid source includes at least 16 wt % linoleic acid and at least 2 wt % α-linolenic acid expressed as a percentage of total fatty acid content in each case and in amounts such that the ratio of linoleic acid:α-linolenic acid is in the range from 1 to 10.

Подробнее
05-01-2012 дата публикации

Process for production of orally ingestible composition containing arabinofuranosyl vitexin, and use of the composition

Номер: US20120004193A1
Автор: Shuichi Kusano
Принадлежит: Fuji Sangyo Co Ltd

A method for producing an orally ingestible composition containing an arabinofuranosyl vitexin and/or a hydrolysate thereof by using Basella alba as a raw material. The product of such method has a sedative effect and a sleep-inducing effect.

Подробнее
12-01-2012 дата публикации

Soybean variety a1023199

Номер: US20120011609A1
Автор: Maqsood Rehman
Принадлежит: MONSANTO TECHNOLOGY LLC

The invention relates to the soybean variety designated A1023199. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1023199. Also provided by the invention are tissue cultures of the soybean variety A1023199 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1023199 with itself or another soybean variety and plants produced by such methods.

Подробнее
19-01-2012 дата публикации

Sustained release of nutrients in vivo

Номер: US20120015039A1
Принадлежит: NEW WORLD PHARMACEUTICALS LLC

Nutritional compositions delivered in vivo in a time controlled manner sustainable over long periods of time, provide enhancing athletic performance, increased hand/eye coordination and concentration on the task at hand.

Подробнее
19-01-2012 дата публикации

Infant or follow-on formula

Номер: US20120015077A1
Принадлежит: Nestec SA

The formula of the invention, intended both for infants and young children, comprises modified sweet whey proteins free or almost free of CGMP, and at least one probiotic. The invention also pertains to methods for promoting physical development, improving gastro intestinal comfort and developing a healthy gut microflora in infants or young children by fully or partly feeding them with the said formula.

Подробнее
26-01-2012 дата публикации

Chocolate flavoured probiotic supplement

Номер: US20120021095A1
Принадлежит: Probiotical SpA

The present invention refers to a food product. In particular, the present invention refers to a form of administration of a high and stable load of probiotic bacteria preferentially to persons of paediatric age. The present invention furthermore refers to a chocolate flavoured probiotic supplement, in particular to a probiotic tablet comprising an inner part, represented by a core of chocolate containing coated probiotic bacteria, and an outer part, represented by an outer coating. In particular, the present invention refers to a form of administration of a high and stable load of probiotic bacteria.

Подробнее
02-02-2012 дата публикации

Methods For Quantifying The Complete Nutritional Value Of A Standard Equivalent Unit Of The Nutritional Value Of One Serving Of Fruits & Vegetables (SFV)And For Fortifying A Base Food To Contain Same For Human Consumption

Номер: US20120027897A1
Автор: Mark A. Innocenzi
Принадлежит: Individual

The described invention provides a method to determine a standard equivalent unit of nutrition in one serving of a weighted composition comprising a basket of fruits and vegetables representing at least 85% of all fruits and vegetables consumed in a defined geographical area; a method to fortify a base food so that the base food contains a standard equivalent unit of nutrition present in at least one serving comprising (i) at least one fruit; (ii) at least one vegetable; or (iii) at least one fruit and at least one vegetable; and a nutritional supplement or food additive comprising a set of nutrititive components wherein the set of nutritive components provides at least one standard equivalent unit of nutrition present in one serving of a composition comprising at least one fruit and at least one vegetable.

Подробнее
02-02-2012 дата публикации

Anti-anxiety composition

Номер: US20120029088A1
Принадлежит: JX Nippon Oil and Energy Corp

This invention provides a highly safe anti-anxiety composition that can be used for treatment or prevention of anxiety disorders. Such anti-anxiety composition comprises, as an active ingredient, a carotenoid.

Подробнее
09-02-2012 дата публикации

Non-tobacco moist snuff composition and a method for its manufacture

Номер: US20120031415A1
Принадлежит: SWEDISH MATCH NORTH EUROPE AB

A non-tobacco snuff composition for oral use including at least one type of plant fibers with a high dietary fiber content, wherein the fiber dietary content in the composition is 15-90 w/w % based on the dry weight of the composition and a method for manufacturing the non-tobacco snuff composition.

Подробнее
09-02-2012 дата публикации

Low calorie dairy products

Номер: US20120034345A1
Принадлежит: Gervais Danone SA

The present invention pertains to fermented dairy products with reduced caloric values, in particular to low-fat, milkshakes and smoothies having reduced amounts in sugar. The dairy products of the invention comprise gelatine. They have high foaming rates and are stable over time. Further, the present invention also relates to processes and kits-of-parts for obtaining said dairy products.

Подробнее
16-02-2012 дата публикации

Isoamyl acetate for weight management

Номер: US20120040046A1
Принадлежит: Nestec SA

Described is the use of isoamyl acetate in food compositions for weight management and/or weight control. Further described is a beverage containing isoamyl acetate.

Подробнее
16-02-2012 дата публикации

Production of soy protein product using calcium chloride extraction "(s702/s7300/s7200/s7301")

Номер: US20120040074A1
Автор: Kevin I. Segall
Принадлежит: Burcon Nutrascience MB Corp

A soy protein product having a protein content of at least about 60 wt % (N×6.25) d.b., preferably a soy protein isolate having a protein content of at least about 90 wt % (N×6.25) d.b., is prepared from a soy protein source material by extraction of the soy protein source material with an aqueous calcium salt solution, preferably calcium chloride solution, to cause solubilization of soy protein from the protein source and to form an aqueous soy protein solution, separating the aqueous soy protein solution from residual soy protein source, concentrating the aqueous soy protein solution while maintaining the ionic strength substantially constant by using a selective membrane technique, optionally diafiltering the concentrated soy protein solution, and drying the concentrated and optionally diafiltered soy protein solution. Alternatively, the concentrated and optionally diafiltered soy protein solution may be diluted into water to cause the formation of a precipitate, separating the precipitate from the diluting water (supernatant), and drying the separated soy protein solution to form a soy protein product having a protein content of at least about 60 wt % (N×6.25) d.b., preferably a soy protein isolate having a protein content of at least about 90 wt % (N×6.25) d.b. The supernatant may be processed to form soy protein products having a protein content of at least about 60 wt % (N×6.25) d.b., preferably a soy protein isolate having a protein content of at least 90 wt % (N×6.25) d.b. Alternatively, the precipitate from the dilution step and diluting water is acidified to resolubilize the precipitate and form a clear soy protein solution. The clear soy protein solution is concentrated while maintaining the ionic strength substantially constant by using a selective membrane technique followed by optional diafiltration and drying.

Подробнее
08-03-2012 дата публикации

Microencapsulation of bioactive substances and methods of making the same

Номер: US20120058195A1
Автор: Moti Harel
Принадлежит: Advanced Bionutrtion Corp

The present invention relates to microparticles and methods of making such microparticles that protect a bioactive substance from heat, humidity and oxidation. A microparticle comprising a bioactive substance, an agglomerating agent, an emulsifier and solid fats is disclosed. A method to produce a microparticle comprising an agglomerated bioactive substance enrobed in a double layer of solid fats and emulsifier is also disclosed.

Подробнее
22-03-2012 дата публикации

Active plastic material in oil

Номер: US20120070880A1
Автор: Elisabeth Sjoberg
Принадлежит: Individual

A method is provided of prolonging the shelf life of probiotic lactic-acid producing bacteria formulated in oil, by using a specific moisture absorbing technology.

Подробнее
12-04-2012 дата публикации

Treatment of inflammatory bowel disease

Номер: US20120087998A1
Автор: Jonathan Rhodes
Принадлежит: Provexis IBD Ltd

The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the Musa spp. The soluble fibre may in particular be derived from plantains or bananas.

Подробнее
19-04-2012 дата публикации

Nutritional beverage formulation

Номер: US20120093981A1
Автор: Leslie J. Minus
Принадлежит: Individual

A nutritional beverage formulation for achievement of optimum health in an individual.

Подробнее
03-05-2012 дата публикации

System and method for enhanced preparation and storage of homemade baby food

Номер: US20120107469A1
Автор: Lenny Sands
Принадлежит: Individual

The present invention describes a system and method for easy, affordable, efficient, and convenient preparation and storage of fresh, high-quality homemade baby food. The system generally comprises a blender for processing fresh produce into baby food and multiple devices to store multiple portions of freshly produced baby food resulting from one use of the system. For example, one component of the system includes a storage cup having a freshness indicator and lid to immediately store the freshly made food in an organized and convenient manner. The method comprises steps of producing the baby food, transferring the food to an appropriate storage receptacle, adjusting an indicator on the storage receptacle to indicate the freshness level of the food, and immediately serving and covering the remaining receptacles to store the unused food.

Подробнее
03-05-2012 дата публикации

Omega-3 Fatty Acid Enriched Baked Foods and Bar Composition

Номер: US20120107478A1
Принадлежит: SOLAE LLC

The present invention relates to compositions and methods for producing baked food compositions and bar compositions with a quantity of long chain fatty acids. Specifically, the baked food compositions and bar compositions comprise a quantity of stearidonic acid (SDA) enriched soybean oil that imparts improved nutritional quality with an amount of long chain fatty acids, but retains the mouthfeel, flavor, odor, and other sensory characteristics associated with typical baked food compositions and bar compositions.

Подробнее
10-05-2012 дата публикации

Xanthan gum and swellable particulate containing composition and uses thereof

Номер: US20120115964A1
Принадлежит: UNIVERSITY OF NOTTINGHAM

This invention relates to a composition comprising at least about 0.2% w/w xanthan gum and at least about 6% w/w of a swellable particulate, and to uses thereof.

Подробнее
17-05-2012 дата публикации

Oleoylethanolamide based functional mesophases

Номер: US20120122990A1
Принадлежит: Nestec SA

The present invention relates to the field of liquid crystals. Embodiments of the present invention relate to liquid crystals comprising at least one molecule within N-acyl ethanolamide (NAE) family, for example oleoylethanolamide (OEA), compositions comprising them and their possible uses.

Подробнее
24-05-2012 дата публикации

Method for encapsulation of an edible oil, compositions comprising edible oil and the use thereof

Номер: US20120128831A1
Принадлежит: Individual

The present invention relates to a method for encapsulation of an edible oil using whey protein and a reducing sugar. The edible oil comprises long chain polyunsaturated fatty acids. Also compositions comprising an edible oil obtainable by the method of the invention are provided. The compositions of the invention have good stability to oxidation, good taste and/or odour, and limited diffusion from and into the continuous phase when applied in liquids. The compositions of the invention are particularly suitable for food and pharma applications.

Подробнее
24-05-2012 дата публикации

Method for suppressing the acrid taste and/or metallic taste derived from potassium chloride

Номер: US20120128862A1
Принадлежит: Individual

There are provided a method by which the acrid taste and/or metallic taste of potassium chloride which is added to food compositions for the purpose of manufacturing low- or reduced-salt products is suppressed in a safe and economical manner without compromising the palatability of the food compositions, as well as an agent for use in this method to suppress the acrid taste and/or metallic taste derived from potassium chloride. The agent contains a yeast-derived peptide containing composition as the active ingredient. The invention is also useful for salt reduction and for the treatment of diseases or conditions that are associated with excessive salt intake, as well as diseases or conditions that can be improved by reducing salt intake.

Подробнее
07-06-2012 дата публикации

Composition including an unsaponifiable fraction

Номер: US20120141387A1
Принадлежит: Laboratoires Expanscience SA

The present invention relates to a composition, notably cosmetic, nutraceutical, dermatological, pharmaceutical or dietary, including at least one unsaponif iable extract, a drug including one such composition, the use of one such composition, a treatment method consisting in administering one such composition and a method comprising the administration of one such composition.

Подробнее
07-06-2012 дата публикации

Nutritional supplement

Номер: US20120141447A1
Автор: Ford D. Albritton, Iv
Принадлежит: Individual

A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.

Подробнее
07-06-2012 дата публикации

Liquid enteral nutritional composition with a low monovalent metal ion content

Номер: US20120142587A1
Принадлежит: Nutricia NV

Heat-treated liquid enteral nutritional composition with a low monovalent metal ion content are provided that contain micellar casein and optionally caseinate, and in which the total amount of monovalent metal ions is less than 25 mg/g of protein. Also, heat-treated liquid enteral nutritional compositions are disclosed comprising 10 to 20 g of protein per 100 ml of the composition, in which all or a major part of said protein comprises micellar casein. Also, a method is disclosed for producing the composition according to the invention, comprising a step wherein an aqueous protein solution in which all or a major part of said protein comprises micellar casein, is subjected to an evaporation step.

Подробнее
21-06-2012 дата публикации

Cosmetic System for Disguising Skin Defects

Номер: US20120152274A1
Автор: Matthew Singer
Принадлежит: Matthew Singer

The present invention provides a cosmetic system for disguising dermatological blemishes. The cosmetic system includes a viscous silicone material and a catalyst. The silicone material or the catalyst is tinted with a cosmetic pigment according to a selected skin tone. In one aspect, the silicone material or the catalyst also includes a flocking agent to provide texture. The cosmetic system may also include one or more dispensers, such as double-barrel syringes. The syringes hold the viscous silicone material and the catalyst, separately. The system also has mixing tips through which the silicone material and the catalyst may be dispensed, whereupon the silicone material and the catalyst are mixed and applied to a user's skin for curing. The cosmetic system is sold together as a package.

Подробнее
28-06-2012 дата публикации

Use of dietary fibres against muscle wasting

Номер: US20120165243A1
Принадлежит: Nutricia NV

A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units.

Подробнее
12-07-2012 дата публикации

Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Номер: US20120177691A1
Принадлежит: Nutricia NV

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

Подробнее
12-07-2012 дата публикации

Green milk

Номер: US20120177802A1
Автор: Xinyue Xu
Принадлежит: Individual

This invention involves in the field of food and beverage and provides green milk comprising whole milk or fermented milk and 0.1-20% by weight of natural phytonutrients or components from herbal cuisine. This invention provides green milk that has balanced nutrients and is easily digested and absorbed by children and seniors. The green milk facilitates the absorption of proteins, vitamins, mineral substances, enzymes, and natural chlorophyll, and provides necessary nutrients that may not be obtained from other daily diet. Statistics show that the green milk is of high nutrition value and the absorbed dose of proteins, vitamins, and mineral substances in green milk is increased by 12.5%˜35.7% comparing to milk only.

Подробнее
26-07-2012 дата публикации

Tangerine peel extract and its preparation and application

Номер: US20120189731A1
Принадлежит: Infinitus China Co Ltd

This invention disclosed is a tangerine peel extract with the effect of weight gain. This extract uses tangerine peel as the raw ingredient and is obtained through extraction processes using supercritical CO 2 , water, or organic solvents. The resulting extraction component contains a large quantity of flavonoids and terpenoids, which can effectively regulate the function of the spleen and stomach leading to desired weight gain. This invention also declares the preparation methods of the above mentioned tangerine peel extraction, which is simple in technique and highly effective in extraction. This invention also further declares the application of the above mentioned tangerine peel extraction in preparing healthcare food with the function of gaining weight.

Подробнее
02-08-2012 дата публикации

Diagnosis and treatment of the prodromal schizophrenic state

Номер: US20120195984A1
Автор: Jay L. Lombard
Принадлежит: Genomind Inc

Described herein are compounds (including medical foods, pharmaceutical compositions, methods of compounding them), methods and systems for the diagnosis and/or treatment of prodromal schizophrenia. For example, described herein are methods of treating a developmentally-based neuropsychiatric disorder (schizophrenia) that includes first determining if a subject is at risk for such a disorder by examining phenotypical, serological immune markers and genotypical biomarkers. The biomarkers may be used to tailor the dose to be delivered by the medial food or pharmaceutical composition. Also described are compounds for treating prodromal (rather than full-blown) schizophrenia.

Подробнее
09-08-2012 дата публикации

Liquid transition nutrition for infants

Номер: US20120201922A1
Принадлежит: Nutricia NV

Liquid composition suitable for supporting the transition period wherein the infant changes from a diet consisting of breast milk or liquid infant formula to solid foods with a viscosity 20-150 mPas, containing a digestible carbohydrate fraction and an indigestible carbohydrate fraction with at least 50 wt. % soluble indigestible oligosaccharide with a degree of polymerisation (DP) between 2 and 100.

Подробнее
09-08-2012 дата публикации

Brewable coffee product containing soluble fiber

Номер: US20120201930A1
Принадлежит: GREEN LEAF FOODS LLC

A brewable coffee product that, when brewed, produces a coffee beverage having an increased amount of dietary fiber as compared to a coffee beverage brewed from traditional ground coffee. The brewable coffee product includes ground coffee beans and at least one plant-derived soluble fiber ingredient.

Подробнее
16-08-2012 дата публикации

Alkaline booster with antioxidants

Номер: US20120207883A1
Автор: Robert Kim
Принадлежит: Individual

A highly alkaline, ultra-low sodium solution of saturated tripotassium phosphate may be used as an additive to dosages such as concentrated drops, tablets, capsules, bottled water, beverages or other dosage forms. The additive further includes organic potassium, calcium, zinc, magnesium, selenium and 79 trace minerals from ancient sea salt. The trace minerals are taken from the low-sodium technical magnesium chloride marine deposits and chelated with amino acids. The amino acids are from a non-animal source which is suitable for vegetarian and persons who are allergic to animal proteins. The additive, which is considered nutritionally nil in sodium content, can be used as a concentrated aqueous drop or dried and used as an additive for dietary supplement dosage forms including tablets, capsules, bottled water, beverages and others.

Подробнее
16-08-2012 дата публикации

Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk

Номер: US20120208782A1
Автор: David Curtis Frantz
Принадлежит: WYETH LLC

A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula.

Подробнее
23-08-2012 дата публикации

Methods for diagnosis and treatment of chronic fatigue syndrome

Номер: US20120214870A1
Принадлежит: University of South Australia

Methods for the diagnosis and treatment of chronic fatigue syndrome (CFS) are disclosed based upon the finding that particular individual acylcarnitines are present in modified concentrations (ie decreased or increased concentrations) in CFS patients compared to healthy control subjects. In one form of the invention, a diagnostic method comprises determining a concentration of at least one individual acylcarnitine compound (eg oleyl-L-carnitine and linoleyl-L-carnitine) in a body sample from a test subject and comparing the concentration to a reference concentration, wherein a difference in the concentration of the at least one individual acylcarnitine from the test subject compared to the reference concentration is indicative of CFS. In another form of the invention, a method of treating CFS is provided which comprises administering an effective amount of a supplement comprising: at least one acylcarnitine compound selected from short-chain, medium-chain and long-chain acylcarnitines, L-carnitine (or an acylcarnitine that may be converted within a subject to L-carnitine) in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids, or at least one acylcarnitine in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids.

Подробнее
30-08-2012 дата публикации

Anti-oxidant Composition

Номер: US20120219689A1
Автор: Lars Mansson
Принадлежит: Danisco AS

The present invention provides an anti-oxidant composition comprising (a) an extract obtained from or obtainable from a plant of the Labiatae family, (b) an extract obtained from or obtainable from a plant of the genus Matricaria or of the genus Chamaemelum

Подробнее
30-08-2012 дата публикации

Composition With Preventive or Improvement Effect on Symptoms or Diseases Associated with Stress-Induced Behavior Disorders

Номер: US20120220660A1
Принадлежит: Suntory Holdings Ltd

A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.

Подробнее
20-09-2012 дата публикации

Method for obtaining natural extracts, oleoresins, condiments, colorants, flavoring substances and aromas from aromatic plant substances, alfalfa, flowers with pigments, and vegetables

Номер: US20120237970A1
Принадлежит: Individual

A method for obtaining natural extracts, oleoresins, colorants flavors and aromas from aromatic plant substances, alfalfa, flowers with pigments, and vegetables, which includes washing the plant substances and vegetables, rinsing with water, milling and sifting the resulting product yielding a pulp phase and a cellulose phase. The pulp phase is transferred to fermentation tanks and a first centrifugation of the fermented pulp phase is then performed yielding two phases: phase (A) containing water, mineral salts and other water-soluble substances, with natural extracts, oleoresins, colorants, aromas and flavors and phase (B) in the form of a paste in which the moisture has been reduced to 50%, performing a second centrifugation of the mentioned phase (A), which causes the separation of natural extracts, oleoresins, colorants, aromas and flavors from the water and other water-soluble substances.

Подробнее
27-09-2012 дата публикации

Methods for improving bone health in infants using long chain polyunsaturated fatty acids

Номер: US20120245121A1
Принадлежит: ABBOTT LABORATORIES

Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.

Подробнее
04-10-2012 дата публикации

Liver function enhancing composition

Номер: US20120251567A1
Автор: Jong Hyun Nam
Принадлежит: Individual

The present invention relates to a composition for the improvement of hepatic functions. More particularly, the present invention relates to a composition including an extract from Albizia julibrissin Durazz as an active ingredient.

Подробнее
04-10-2012 дата публикации

Devices and methods for weight control and weight loss

Номер: US20120251589A1
Автор: Paolo Costa
Принадлежит: TERATEKNE Inc

The present invention provides, compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material. In various embodiments, the matrix material is suitable for routine use. The compressible absorbent matrix material has a size, shape and/or geometry configured for efficient packing into a small space, and/or configured to absorb and substantially retain digested material in the stomach. The devices and compositions may further comprise one or more hydrogel(s), soluble or insoluble fibers, waxes and/or gums to provide the desired mechanical properties and/or absorptive or shielding properties.

Подробнее
11-10-2012 дата публикации

Isotonic beverage with chelates

Номер: US20120258087A1
Принадлежит: OLIMP LABS SP z oo

The subject of the invention is an isotonic beverage with chelates containing carbohydrates, mineral amino acid chelates, L-carnitine, sweeteners, flavouring substances, and a diluent, the essential feature of the beverage being the content of up to 0.1 wt % of mineral components in the form of mineral amino acid chelates, preferably bisglycinates and glycinates, from 0.1 to 50 wt % of isomaltulose, up to 15 wt % of L-carnitine and/or its derivatives, from 5 to 84% of carbohydrates, up to 50 wt % of bioactive substances, up to 50 wt % of flavouring substances, up to 80 wt % of polyalcohols, diluents, tableting aids, stabilizers, antioxidants, dyes, and 0.013-25 wt % of sweeteners, whereby its osmolarity is 275-295 mOsm/kg and pH is 2-5.

Подробнее
11-10-2012 дата публикации

Composition with high protein content for the food industry

Номер: US20120258236A1
Принадлежит: Team Foods Colombia SA

The invention relates to a novel protein composition comprising sources of both animal and vegetable origin, having a high PDCAAS nutritional quality value and containing essential amino acids better than those of the proteins in a whole egg, as well as essential amino acids similar to or better than those in meat, suitable for use in pastries, extruded snacks, pastries and meat products.

Подробнее
18-10-2012 дата публикации

Preparation method of the compounds for absorbing heavy metals

Номер: US20120264199A1
Автор: Yung-Cheng Lin
Принадлежит: Individual

The present invention is related to a preparation method of the compounds for absorbing heavy metals. First of all, prepare natural vegetable or fruit and extract a B-M sulfur peptide from the said natural vegetable or fruit. Second, place the natural vegetable or fruit into fermentation and extract the mixed nutrient extraction. And then mix the B-M sulfur peptide and the mixed nutrient extraction as the final extraction. Mix the final extraction into drinks. The final extraction will slowly release B-M sulfur peptide when entering the body; through its combination of heavy metals and re-absorption by the body, useful materials are retained in the human body while long-term accumulated toxic metals are discharged to repair the body's metabolism.

Подробнее
01-11-2012 дата публикации

Plasticized Elastomer Including a Volatile Compound

Номер: US20120273586A1
Принадлежит: Individual

A plasticized elastomer includes a polymeric carrier and a volatile compound, such as a fragrance, medicament, or antimicrobial, disposed in the polymeric carrier. The polymeric carrier absorbs microwave energy and slowly dissipates it as heat until the polymeric carrier reaches thermal equilibrium with the ambient temperature. The heat of the polymeric carrier increases a vapor pressure of the volatile compound, which boosting its evaporation into the ambient environment.

Подробнее
15-11-2012 дата публикации

Functional cereal formulation

Номер: US20120288588A1
Автор: Jon Barron
Принадлежит: Individual

Nutritional or functional food compositions comprise a combination of brown rice protein isolate, yellow pea protein isolate, and hemp protein isolate. The food compositions are hypoallergenic and highly bioavailable. Methods of making suitable RTD formulations are described.

Подробнее
22-11-2012 дата публикации

Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics

Номер: US20120294840A1
Принадлежит: Glycosyn Trustees of Boston College LLC

The invention provides compositions and methods for utilizing synthetic human milk oligosaccharides as prebiotics.

Подробнее
29-11-2012 дата публикации

Dietary regimens useful for mimicking caloric restrictions

Номер: US20120301559A1
Принадлежит: Individual

The invention provides dietary regimens useful mimicking caloric restriction in animals. The regimens use a first diet containing one or more dietary supplements suitable for mimicking caloric restriction when the animal is a young animal; a second diet containing one or more dietary supplements suitable for mimicking caloric restriction when the animal is an adult animal; and a third diet containing one or more dietary supplements suitable for mimicking caloric restriction when the animal is a senior animal; wherein the dietary supplements in the first diet, second diet, and third diet are not all be the same dietary supplements.

Подробнее
06-12-2012 дата публикации

Emulsion or Gel for Producing food Products Including Omega-3 Fatty Acid

Номер: US20120308704A1

An emulsion as an ingredient or additive for producing food products including omega-3 fatty acids, the emulsion including an outer water phase including at least one water soluble antioxidant that is dissolved in water; and an inner fat or oil phase which includes plant oil droplets provided with at least one fat or oil soluble antioxidant and with omega-3 fatty acid ester, wherein the plant oil droplets are respectively provided with a shell made from plant protein.

Подробнее
06-12-2012 дата публикации

Drink

Номер: US20120308711A1
Принадлежит: Cognis IP Management GmbH

The present invention relates to a drink which is an oil-in-water emulsion and which comprises hydrocolloids, where the hydrocolloids are a mixture of gellan and pectin. The hydrocolloids prevent or retard the creaming of the oil phase or fat phase of the oil-in-water emulsion.

Подробнее
10-01-2013 дата публикации

Dried fermented dairy product containing a high density of living bifidobacteria

Номер: US20130011517A1
Принадлежит: Individual

The present invention concerns a dried fermented dairy product containing living bifidobacteria at a minimal concentration of about 8·10 7 cfu/g, preferably for at least 3 months at room temperature. The invention also relates to a method for preparing same, and to uses of such a product in the food industry.

Подробнее
10-01-2013 дата публикации

Use

Номер: US20130011828A1
Принадлежит: DUPONT NUTRITION BIOSCIENCES APS

The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.

Подробнее
17-01-2013 дата публикации

Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication

Номер: US20130017276A1
Автор: Gregory Blackman

The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames.

Подробнее
17-01-2013 дата публикации

Multicarotenoid beadlets and related method

Номер: US20130017292A1
Принадлежит: ACCESS BUSINESS GROUP INTERNATIONAL LLC

A controlled release beadlet that sequentially releases carotenoids over time within the gastrointestinal tract of a subject, as well as a method of administering the carotenoids. The beadlet provides a specific ratio of carotenoids which release from the beadlet at preselected times during passage through the gastrointestinal tract. The method includes releasing the carotenoids in preselected ratios at specific time intervals in the gastrointestinal tract to mitigate competition between the carotenoids for their uptake, and/or to potentially maximize the uptake of individual carotenoids within a mixed carotenoid formulation.

Подробнее
17-01-2013 дата публикации

Nutritional supplement for the enhancement of muscle performance and recovery

Номер: US20130018102A1
Принадлежит: MAXIMUM HUMAN PERFORMANCE LLC

Described herein are nutritional supplements containing α-hydroxy-isocaproic acid and aspartic acid (e.g., DAA) and their methods of use in enhancing muscle performance and/or recovery after exercise. The nutritional supplements can be used to enhance muscle building and lean body mass, enhance muscle and physical performance, enhance recovery, and prevent catabolism (muscle atrophy or wasting) when administered to a mammalian subject.

Подробнее
24-01-2013 дата публикации

Liquid enteral nutritional composition suitable for tube feeding, minimizing lower and upper tract digestive conditions

Номер: US20130023468A1
Принадлежит: Nutricia NV

The invention is directed to liquid enteral nutritional compositions comprising a protein fraction comprising more than 25 weight % and up to 80 weight % of a vegetable protein comprising at least a source of pea protein, and a fat fraction comprising (a) 8 to 15 weight % of linoleic acid; (b) 3.0 to 6.0 weight % of a combination of alpha-linolenic acid, docosahexaenoic acid and eicosapentaenoic acid, wherein the amount of ALA is >2.5 weight % and the combined amount of DHA and EPA is ≦2.5 weight %; (c) 10 to 20 weight % of at least one medium-chain fatty acid; and (d) 35 to 79 weight % of at least one mono-unsaturated fatty acid. The compositions provide for a healthy and balanced diet, which is well-tolerated and minimises clinical complications that are frequently associated with the administration of enteral nutrition in patients using tube feeding, especially with respect to a reduced gastric emptying.

Подробнее
31-01-2013 дата публикации

Use of black soybean hull extracts in manufacture of products for preventing and treating osteoarthritis

Номер: US20130030046A1

The application relates to a use of black soybean hull extracts in the manufacture of foods, health care products and medicaments. The black soybean hull extracts can be added to foods or drinks, and also can be made into all kinds of oral health care products and oral medicaments used by conventional methods of preparing traditional Chinese medicine preparations. The products can significantly improve symptoms of osteoarthritis, and also can stabilize or even reverse the degradation of cartilage of osteoarthritis.

Подробнее
21-02-2013 дата публикации

Compositions and methods for the prevention of cardiovascular disease

Номер: US20130045193A1
Принадлежит: Angel E. Gil, Jesus G. Gil, Michael J. Gonzalez

The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ 10 , natural Omega-3 fatty acids, natural bioflavonoids, natural vitamin E, amino acids and derivatives thereof, minerals, extra virgin olive oil, lecithin, B-complex vitamins, and antioxidants.

Подробнее
21-02-2013 дата публикации

Composition for promoting the activity of peroxisome proliferator-activated receptor-delta

Номер: US20130045289A1
Принадлежит: Amorepacific Corp

Disclosed is a composition for promoting the activity of peroxisome proliferator-activated receptor-δ (PPAR-δ), which contains Artemisia vulgaris extracts or Artemisia capillaris extracts as active ingredients. The composition is effective in strengthening muscles, improving endurance and memory, and preventing and alleviating the symptoms of dementia or Parkinson's disease.

Подробнее
28-02-2013 дата публикации

Composition for treatment of aesthenopia

Номер: US20130052286A1
Принадлежит: Nihon Pharmaceutical Co Ltd

This is to provide a novel medicine and a food and a drink composition for treating aesthenopia excellent in improved effect of aesthenopia. The composition for the treatment of aesthenopia comprises chondroitin sulfate or a salt thereof.

Подробнее
28-02-2013 дата публикации

Egg substitute and method of producing same

Номер: US20130052304A1
Автор: Weili Li
Принадлежит: Individual

An egg substitute composition comprising wheat protein, emulsifiers, at least one fat or oil, and polysaccharides, and optionally supplementary proteins and food gums. The composition preferably includes 1-90% wheat protein, 1-30% fat or oil and 5-30% polysaccharides. Optionally 0-50% supplementary proteins, 0-30% emulsifiers, 0-10% food gums, 0-3% reducing-oxidant agents and 0-5% calcium and ferrous salts. The composition also includes 0.01-1% sodium phosphate and disoldium phosphate in liquid form egg replacer.

Подробнее
07-03-2013 дата публикации

Polypeptide shaving transgalactosylating activity

Номер: US20130059034A1
Принадлежит: DUPONT NUTRITION BIOSCIENCES APS

The present invention relates to polypeptides, specifically polypeptides having transgalactosylating activity and nucleic acids encoding these, and their uses in e.g. dairy product.

Подробнее
21-03-2013 дата публикации

GELS FOR TRANSDERMAL DELIVERY

Номер: US20130071450A1
Автор: Copp-Howland Warren
Принадлежит: COVIDIEN LP

The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes. 1. A medical electrode comprising:a substrate;a conductive composition on at least a portion of a surface of the substrate, the conductive composition comprising at least one hydrogel comprising:{'sub': '2', 'a polymeric component comprising a copolymer comprising a first monomer comprising a mixture of acrylic acid and a salt thereof, present in an amount of from about 8 weight % to about 85 weight % of the copolymer, and a second monomer of the formula CH═CHC(O)XR, in which X is O or NH and R is an unsubstituted or substituted alkyl group of from about 1 to about 5 carbon atoms present in an amount of from about 15 weight % to about 92 weight % of the copolymer;'}at least one penetration enhancer selected from the group consisting of sulfoxides, alcohols, pyrrolidones, laurocapram, solvents, fatty alcohols, amides, amino acids, azones, oils, fatty acids and their esters, macrocycles, phospholipids, glycols, and combinations thereof; andat least one bioactive agent.2. The medical electrode of claim 1 , wherein the penetration enhancer is selected from the group consisting of dimethylsulfoxide claim 1 , decylmethyl sulfoxide claim 1 , tetradecylmethyl sulfoxide claim 1 , methanol claim 1 , ethanol claim 1 , 2-propanol claim 1 , 2-pyrrolidone claim 1 , N-methyl-2-pyrrolidone claim 1 , N-(2-hydroxyethyl)pyrrolidone claim 1 , acetone claim 1 , dimethyl acetamide claim 1 , dimethyl formamide claim 1 , tetrahydrofurfuryl alcohol claim 1 , lauryl alcohol claim 1 , N claim 1 ,N-diethyl-m-toluamide claim 1 , L-amino acids claim 1 , menthol claim 1 , peppermint oil claim 1 , oleic acids claim 1 , lauryl acids claim 1 , isopropyl myristate claim 1 , glycerol ...

Подробнее
21-03-2013 дата публикации

COMPOSITIONS AND METHODS FOR TREATING SIGNS OF SKIN AGING

Номер: US20130071500A1

The invention relates to methods and compositions for treating skin aging, said compositions comprising at least one tropoelastin promoter and at least one tropoelastin crosslinker. 129-. (canceled)30. A cosmetic composition comprising: (a) a tropoelastin promoter selected from the group consisting of feverfew extract , bimetal complexes having copper and/or zinc constituents , and combinations thereof; (b) dill extract; and (c) a cosmetically acceptable carrier.31. The cosmetic composition according to claim 30 , wherein said tropoelastin promoter is present in an amount comprising from about 0.1% to about 10% by weight of the composition.32. The cosmetic composition according to claim 30 , wherein said tropoelastin promoter is present in an amount comprising from about 0.5% to about 5% by weight of the composition.33. The cosmetic composition according to claim 30 , wherein said dill extract is present in an amount comprising about 0.1% to about 10% by weight of the composition.34. The cosmetic composition according to claim 30 , wherein said dill extract is present in an amount comprising about 0.5% to about 5% by weight of the composition.35. The cosmetic composition according to claim 30 , wherein said tropoelastin promoter has a Tropoelastin Promoter Activity of at least about 1.2.36. A method of treating a sign of skin aging claim 30 , comprising topically applying to skin in need of such treatment a cosmetically effective amount of a composition comprising: (a) a tropoelastin promoter selected from the group consisting of feverfew extract claim 30 , bimetal complexes having copper and/or zinc constituents claim 30 , and combinations thereof; (b) dill extract; and (c) a cosmetically acceptable carrier.37. The method according to claim 36 , wherein said sign of skin aging is selected from the group consisting of lines claim 36 , wrinkles claim 36 , loss of elasticity claim 36 , uneven skin claim 36 , blotches claim 36 , and age spots.38. The method according ...

Подробнее
21-03-2013 дата публикации

EXTRACT OF STEWARTIA KOREANA AND USE THEREOF

Номер: US20130071501A1
Принадлежит: RNA, INC.

The present invention relates to an extract of and use thereof More particularly, it relates to an extract of which is extracted with any one selected from the group consisting of water, a Clow alcohol, a polar solvent, a non-polar solvent and a mixture thereof, and a pharmaceutical composition for promoting angiogenesis or tissue regeneration and a cosmetic for improving wrinkles comprising the same as an effective ingredient. The extract of promotes migration and multiplication of endothelial cell and shows excellent effect in angiogenesis and wound healing and is useful in treatment or prevention of diseases which requires angiogenesis for healing of wounded and frostbitten region, wound healing after surgical operation, and treatment and prevention of gastric ulcer, ischaemic heart diseases and hair loss. Also, the extract shows the dermal tissue regenerating effect and is useful as a cosmetic for improving wrinkles 18.-. (canceled)9Stewartia koreana. A method for promoting angiogenesis in a subject in need thereof , the method comprising administering an extract of to the subject.10Stewartia koreana. The method for promoting angiogenesis according to claim 9 , wherein the extract of is extracted with any one solvent selected from the group consisting of water claim 9 , a C1-4 low alcohol claim 9 , a polar solvent claim 9 , a non-polar solvent claim 9 , and a mixture thereof.11Stewartia koreana. The method for promoting angiogenesis according to claim 9 , wherein the extract of is prepared by the following steps:{'i': 'Stewartia koreana', '(a) adding leaves of in any one solvent selected from the group consisting of water, a C1-4 low alcohol, a polar solvent, a non-polar solvent, and a mixture thereof and performing extraction under reflux at about 40 to about 80° C. while stirring;'}(b) isolating a filtrate by filtration of the extract; and(c) obtaining a powder by concentrating the filtrate at reduced pressure.12. The method for promoting angiogenesis ...

Подробнее
21-03-2013 дата публикации

HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE

Номер: US20130072453A1
Принадлежит: ALLERGAN, INC.

The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well. 1. A stable dermal filler formulation comprising a mixture of a hyaluronic acid (HA) and phenylephrine.2. The dermal filler formulation of claim 1 , wherein stability of the dermal filler formulation is determined by subjecting the dermal filler formulation to a heat treatment selected from the group consisting of (a) steam sterilization at between about 120° C. and about 135° C. claim 1 , and (b) about 32 days at about 45° C. claim 1 , with substantial retention after the heat treatment of one or more of the dermal filler characteristics of being clear claim 1 , homogenous claim 1 , and cohesive claim 1 , and without substantial degradation of the dermal filler formulation after the heat treatment.3. The dermal filler formulation of claim 1 , wherein the HA is cross-linked.4. The dermal filler formulation of claim 1 , wherein the HA is present in the composition in an amount of about 1 to about 40 mg/mL.5. The dermal filler formulation of claim 1 , wherein the formulation is stable claim 1 , as determined by substantial retention at room temperature of one or more of the dermal filler characteristics of being clear claim 1 , homogenous claim 1 , and cohesive claim 1 , and without substantial degradation of the dermal filler formulation claim 1 , for a period of at least 2 years.6. The dermal filler formulation of claim 5 , wherein the formulation is stable for at least 3 years.7. The dermal filler formulation of claim 1 , wherein the phenylephrine is present in the composition in an amount of about 0.001% to about 10% w/w.8. The dermal filler formulation of further comprising lidocaine.9. The dermal filler formulation of further comprising lidocaine in an ...

Подробнее
21-03-2013 дата публикации

6,9-Disubstituted Purine Derivatives and Their Use for Treating Skin

Номер: US20130072505A1
Принадлежит:

The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives. 2. The method of claim 1 , wherein Ris furfuryl or methoxy-substituted furfuryl and Ris 2-tetrahydropyranyl.3. The method of claim 1 , wherein Ris furfuryl and Ris 2-tetrahydropyranyl.4. The method of claim 1 , wherein the amount is about 0.05 to about 10 percent.5. The method of claim 2 , wherein the amount is about 0.05 to about 10 percent.6. The method of claim 3 , wherein the amount is about 0.05 to about 10 percent.7. The method of claim 1 , wherein the amount is about 0.1 to about 2 percent.8. The method of claim 2 , wherein the amount is about 0.1 to about 2 percent.9. The method of claim 3 , wherein the amount is about 0.1 to about 2 percent.10. (canceled)11. (canceled)13. The method of claim 12 , wherein the amount is about 0.05 to about 10 percent.14. The method of claim 12 , wherein the amount is about 0.1 to about 2 percent.15. The method of claim 12 , wherein the mammalian skin is human skin.16. The method of claim 13 , wherein the mammalian skin is human skin.17. The method of claim 14 , wherein the mammalian skin is human skin.19. The method of claim 18 , wherein the amount is about 0.05 to about 10 percent.20. The method of claim 18 , wherein the amount is about 0.1 to about 2 percent. The present application is a continuation of utility application Ser. No. 13/116,636 filed on May 26, 2011, which was a continuation of utility application Ser. No. 12/786,027, filed on May 24, 2010, which was a continuation of utility application Ser. No. 11/774,652, filed on Jul. 9, 2007, which is related to, and based on, U.S. Provisional Application 60/806,871, filed on Jul. 10, 2006, to which priority is claimed, all of which are ...

Подробнее
21-03-2013 дата публикации

6,8-DISUBSTITUTED PURINE COMPOSITIONS

Номер: US20130072506A1
Принадлежит:

6,8-Disubstituted purines which can be used in drug and cosmetic compositions and/or applications are provided. These 6,8-disubstituted purines have a wide range of biological activities, including for example anti-inflammatory, anti-senescent, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. The 6,8-disubstituted purine compounds and compositions containing such 6,8-disubstituted purines provide growth-regulatory, differentiating, antisenescent and antiaging properties with improved selectivities and efficiencies and lower toxicities than analogues known heretofore. 2. The 6 claim 1 ,8-disubstituted purines of claim 1 , wherein Ris selected from the group consisting of furfuryl claim 1 , phenyl claim 1 , benzyl claim 1 , 3-methylbut-2-en-1-yl claim 1 , cyclohexylmethyl claim 1 , allyl claim 1 , and 3 claim 1 ,3-dimethylallyl claim 1 , wherein the selected Rcan be unsubstituted or substituted with one or more halogen claim 1 , hydroxy claim 1 , methoxy claim 1 , methyl claim 1 , amino claim 1 , nitro or combinations thereof.3. The 6 claim 1 ,8-disubstituted purines of claim 1 , wherein R8 is selected from the group consisting of amino claim 1 , hydroxy claim 1 , chloro claim 1 , fluoro claim 1 , bromo claim 1 , amino(C-Calkyl)amino claim 1 , hydroxy(C-Calkyl)amino claim 1 , NHOH claim 1 , NHNH claim 1 , carboxyl claim 1 , nitro claim 1 , sulphanyl claim 1 , methylsulphanyl claim 1 , and methoxy.4. The 6 claim 3 ,8-disubstituted purines of claim 3 , wherein R8 is amino.5. The 6 claim 1 ,8-disubstituted purines of claim 1 , wherein the 6 claim 1 ,8-disubstituted purines are 6-furfurylamino-8-(amino claim 1 , hydroxy claim 1 , chloro claim 1 , fluoro claim 1 , bromo claim 1 , amino(C-Calkyl)amino claim 1 , hydroxy(C-Calkyl)amino claim 1 , NHOH claim 1 , NHNH claim 1 , carboxyl claim 1 , nitro claim 1 , sulphanyl claim 1 , methylsulphanyl claim 1 , methoxy)purine claim 1 , 6-(3-hydroxybenzylamino)-8-(amino ...

Подробнее
21-03-2013 дата публикации

Cationic Nanogels For Biotechnological Applications

Номер: US20130072576A1
Принадлежит:

The present invention relates to a biocompatible cationic nanogel comprising a polymer network, said polymer network comprising polymer units interconnected with one another through a cross-linking agent, wherein said polymer network can be obtained by polymerizing N-vinylcaprolactam and a cross-linking agent in a dispersed medium, in the presence of a cationic initiator and a cationic or non-ionic emulsifier. The invention also relates to methods for obtaining the mentioned nanogels as well as to pharmaceutical compositions comprising them. 1. A biocompatible cationic nanogel comprising a polymer network , said polymer network comprising polymer units interconnected with one another through a cross-linking agent , wherein said polymer network is obtainable by polymerizing N-vinylcaprolactam and a cross-linking agent in a dispersed medium , in the presence of a cationic initiator and a cationic or non-ionic emulsifier.2. The nanogel according to claim 1 , wherein said cross-linking agent is a difunctional monomer comprising at least two vinyl groups.3. The nanogel according to claim 2 , wherein the cross-linking agent is selected from ethylene glycol dimethacrylate (EGDMA) claim 2 , polydiethylene glycol dimethacrylate (PEGDMA) claim 2 , ethylene glycol diacrylate (EGDA) claim 2 , polydiethylene glycol diacrylate (PEGDA) claim 2 , ethylene glycol di(1-methacryloyloxy)ethyl ether claim 2 , N claim 2 ,N′-methylenebisacrylamide (BA) claim 2 , a dextran with more than one vinyl group claim 2 , and mixtures thereof.4. The nanogel according to claim 1 , wherein the cationic initiator is selected from the group consisting of 2 claim 1 ,2-azobis(N claim 1 ,N′-dimethylene isobutyramidine)dihydrochloride (ADIBA) claim 1 , 2 claim 1 ,2′-azobis[2-(2-imidazolin-2-yl)propane]disulfate dihydrate claim 1 , 2 claim 1 ,2′-azobisisobutyramidine dihydrochloride (AIBA) claim 1 , 2 claim 1 ,2′-azobis{2-[1-(2-hydroxyethyl)-2-imidazolin-2-yl]propane}dihydrochloride and 2 claim 1 ,2′-azobis ...

Подробнее
28-03-2013 дата публикации

SKIN ANTIAGING TREATMENT

Номер: US20130078295A1
Принадлежит: LIPOTEC S.A.

A method for skin antiaging treatment including administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition having a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived peptide, and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant. 1. A method for skin antiaging treatment comprising:a. The administration of an effective amount of Botulinum toxin to an area of facial and/or neck skin, [{'br': None, 'sub': 1', '2, 'R-AA-R\u2003\u2003(I)'}, 'its stereoisomers, mixtures thereof, and/or its cosmetically or pharmaceutically acceptable salts thereof, in which AA is a sequence selected from the group consisting of SEQ ID No.11, SEQ ID No.4, or a sequence of 7 to 12 adjacent amino acids contained in SEQ ID No.4, wherein said sequence comprises the amino acid sequence of SEQ ID No.11;', 'wherein:', {'sub': 1', '5, 'Ris selected from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group, substituted or non-substituted alicyclyl, substituted or non-substituted heterocyclyl, substituted or non-substituted heteroarylalkyl, substituted or non-substituted aryl, substituted or non-substituted aralkyl and R—C(O)—; and'}, {'sub': 2', '3', '4', '3', '3', '3', '4, 'Ris selected from the group consisting of —NRR, —ORand —SR; where Rand Rare independently selected from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group, substituted or non-substituted alicyclyl, substituted or non-substituted heterocyclyl, substituted or non-substituted heteroarylalkyl, substituted or non-substituted aryl and substituted or non-substituted aralkyl;'}, {'sub': '5', 'wherein Ris selected from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group, substituted or non-substituted alicyclyl, substituted or non- ...

Подробнее
28-03-2013 дата публикации

Low protein infant formula with increased essential amino acids

Номер: US20130079276A1
Принадлежит: Nurticia NV

The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula.

Подробнее
04-04-2013 дата публикации

Compositions, kits and methods for nutrition supplementation

Номер: US20130084344A1
Принадлежит: Chemo France SA

The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include twelve carbon chain fatty acids and/or twelve carbon chain acylglycerols, vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.

Подробнее
04-04-2013 дата публикации

Methods and compositions for improving the nutritional content of mushrooms and fungi

Номер: US20130084362A1
Принадлежит: PENN STATE RESEARCH FOUNDATION

An improved filamentous fungi is disclosed that has an enhanced nutritional profile by utilizing pulsed ultraviolet irradiation. According to the invention, the vitamin D component of mushrooms and other filamentous fungi may be drastically increased with no deleterious affects on appearance with the use of pulsed UV radiation. Mushrooms so treated had up to 1800% DV in one serving of fresh mushrooms.

Подробнее
04-04-2013 дата публикации

Process of preparing burdock composite micron essence

Номер: US20130084380A1
Принадлежит: DONG YUAN BIOTECH PHARMACEUTICAL CO Ltd

A process of preparing a burdock composite micron essence at least includes the following. Dissolved and heated phospholipid is added to a vegetable oil extract and then stirred. After stirring, the above mixture is pour into a heated glycerol and then further stirred and a burdock extract aqueous solution is added. The aforementioned mixed solution is stirred at high speed, the emulsion-homogenized solution is subject to high-pressure homogenization, and a filtration membrane is used to filter the homogenized solution obtained to get a purple transparent burdock concentrate. The burdock concentrate is used to prepare the formulation of nano-micro emulsion which is easily absorbed by human body and thus grants improved health benefits.

Подробнее
04-04-2013 дата публикации

COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY

Номер: US20130085170A1
Принадлежит: PROFESSIONAL DIETETICS S.R.L.

Composition comprising leucine, isoleucine, valine threonine and lysine for treating angiogenic disorders in elderly subjects. 115.-. (canceled)16. A method for treating an angiogenic disorder in a mammal , comprising administering thereto a therapeutically effective amount of a pharmaceutical composition comprising leucine andat least one of isoleucine and valine, andat least one of threonine and lysine.17. The method according to claim 16 , wherein the angiogenic disorder affects one of the cardiac muscle and the brain.18. The method according to claim 16 , wherein the angiogenic disorder is one of hypoxia and stenosis.19. The method according to claim 16 , wherein the composition is administered for oral route.20. The method according to claim 16 , wherein the composition is administered chronically over a long period of time claim 16 , preferably extended over at least 60 days.21. The method according to claim 16 , wherein the composition comprises isoleucine claim 16 , and wherein leucine and isoleucine are in a molar ratio comprised in the range of 1:0.2-0.7 claim 16 , preferably between 1:0.4-0.6.22. The method according to claim 16 , wherein the composition comprises valine claim 16 , and wherein leucine and valine are in a molar ratio comprised in the range of 1:0.2-0.8 claim 16 , preferably between 1:0.4-0.7.23. The method according to claim 16 , wherein the composition comprises threonine claim 16 , and wherein leucine and threonine are in a molar ratio comprised in the range of 1:0.15-0.50 claim 16 , preferably between 1:0.20-0.45.24. The method according to claim 16 , wherein the composition comprises lysine and wherein leucine and lysine are in a molar ratio comprised in the range of 1:0.15-0.60 claim 16 , preferably between 1:0.30-0.55.25. The method according to claim 16 , wherein the composition comprises leucine claim 16 , isoleucine and valine in a weight ratio substantially equivalent to 2:1:1.26. The method according to claim 16 , wherein the ...

Подробнее
11-04-2013 дата публикации

Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes

Номер: US20130089638A1
Принадлежит: Mead Johnson Nutrition Co

Compositions comprising maltotriose are disclosed herein. In certain embodiments, the compositions comprise maltotriose and at least one component whose function is subject to impairment by a dehydration process, such as a live microorganism. Methods for inhibiting damage caused by dehydration are also disclosed herein. In particular embodiments, the method includes preparing a composition comprising maltotriose and at least one component whose function is subject to impairment by a dehydration process and removing water from the composition by one or more dehydration processes.

Подробнее
11-04-2013 дата публикации

Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents

Номер: US20130090287A1
Принадлежит: INTARCIA THERAPEUTICS, INC.

The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention. 1. An osmotic delivery device comprising:a beneficial agent formulation comprising (i) a non-aqueous, viscous vehicle comprising a solvent and a polymer, the vehicle having a viscosity of between about 12,000 to about 18,000 poise at 33° C., and (ii) a particle formulation comprising two or more polypeptides, wherein the two or more polypeptides are selected from the group consisting of GLP-1, exendin-4, PYY, and oxyntomodulin; wherein the particle formulation is suspended in the non-aqueous, viscous vehicle.2. (canceled)3. The device of claim 1 , wherein the two or more polypeptides are formulated into one particle formulation that is suspended in the vehicle.4. The device of claim 1 , wherein a first polypeptide is formulated into a first particle formulation and a second polypeptide is formulated into a second particle formulation claim 1 , and the first and second particle formulations are suspended in the vehicle.5. The device of claim 1 , wherein a first polypeptide is exendin-4 and a second polypeptide is oxyntomodulin.6. The device of claim 1 , wherein a first polypeptide is exendin-4 and a second polypeptide is PYY. ...

Подробнее
18-04-2013 дата публикации

TOPICAL USE OF THIAZOLIDINE DERIVATIVES AGAINST CONSEQUENCES OF OXIDATIVE STRESS OF SKIN

Номер: US20130095052A1
Принадлежит: EXSYMOL S.A.M.

The invention concerns a cosmetic care method for opposing destructive effects of oxidative stress and its toxic by-products, comprising administering topically to a patient in need thereof, a derivative of formula (I): 2. The method according to claim 1 , wherein said derivative is administered against stress generating free radicals or reactive oxygen species.3. The method according to claim 1 , wherein said derivative is administered for generating taurine under reactive oxygen species.4. The method according to claim 1 , wherein said derivative is administered for neutralizing toxic electrophile species issued from lipid peroxidation claim 1 , such as 4-hydroxynonenal.5. The method according to claim 1 , wherein the step of administering is done in response to exposure to ultraviolet radiation claim 1 , atmospheric pollution claim 1 , chemical xenobiotics or smoky atmospheres.6. The method according to claim 5 , wherein the exposure is to ultraviolet radiation.7. The method according to claim 1 , wherein the step of administering topically to a patient in need thereof is to skin.9. The method according to claim 8 , wherein said taurine precursor is present between 0.01 and 10% in weight in relation to the total weight of the composition.10. The method according to claim 8 , wherein said physiologically compatible skin excipient is selected from a surfactant claim 8 , a preservative claim 8 , body fat claim 8 , a colorant claim 8 , an emulsifier claim 8 , a gelling agent claim 8 , an emollient claim 8 , a moisturizer claim 8 , a pigment.11. The method according to claim 8 , wherein said composition further comprises an agent selected from the group consisting of antioxidant claim 8 , antiradical and anti-pollution agents.12. The method according to claim 8 , wherein said composition further comprises one or more agent selected from the group consisting of organic UV-A sunscreen claim 8 , organic UV-B sunscreen claim 8 , inorganic UV-A sunscreen claim 8 , ...

Подробнее
18-04-2013 дата публикации

SOL-GEL DERIVED BIOACTIVE GLASS POLYMER COMPOSITE

Номер: US20130095147A1

A bioactive sol-gel solution includes a biocompatible polymer, a gelable inorganic base material, and at least one calcium and phosphorous molecular species. The base material can be an alkoxide, such as TEOS. The polymer acts as a viscosity modifier to the sol or gel, increases the viscosity range over which fibers can be sprayed or spun, and broadens the time period over which fibers can be sprayed or spun. A bioactive glass composite can be formed from the bioactive sol-gel solution, including a fibrous form. Fibers can serve as a scaffolds for cell growth and in the repair of hard or soft tissue defects. 1. A bioactive sol-gel solution , comprising:a biocompatible polymer,a gelable inorganic base material, andat least one calcium and phosphorous molecular species.2. The solution of claim 1 , wherein said base material comprises at least one alkoxysilane.3. The solution of claim 1 , wherein said base material comprises at least one non-alkoxysilane alkoxide selected from the group consisting of aluminates claim 1 , titanates and borates.4. The solution of claim 1 , wherein said polymer comprises at least one selected from the group consisting of polyvinylpyrrolidone (PVP) claim 1 , polyethyleneimine (PEI) claim 1 , polycarboxylmethylcellulose (PCMC) claim 1 , polyethylenglycol (PEG) claim 1 , polypropylene oxide (PPO) claim 1 , polyvinylalcohol (PVA) claim 1 , polyacrylic acid (PAA) claim 1 , polymethylacrylic acid (PMAA) polystyrene sulfonic acid (PSSA) claim 1 , and gelatin.5. The solution of claim 1 , wherein a pH of said solution is from 1 to 7.6. The solution of claim 5 , wherein said pH is from 1.2 to 2.7. The solution of claim 1 , wherein a viscosity of said solution at 25 C is from 1.5 Pa sec. to 6.0 Pa sec.8. The solution of claim 1 , wherein said solution is stable for at least 30 days at 25 C.9. The solution of claim 1 , further comprising at least one biologically active agent claim 1 , wherein said solution forms an encapsulation layer around said ...

Подробнее
18-04-2013 дата публикации

ADHESIVE COMPOSITION FOR MEDICAL USE, PATCH FOR MEDICAL USE, AND METHOD FOR PRODUCING THE COMPOSITION

Номер: US20130095166A1
Принадлежит: TOAGOSEI CO., LTD.

An adhesive composition for medical use of the present invention includes an acrylic copolymer, a medicament having a carboxyl group, and a base, the acrylic copolymer is prepared by copolymerization of a monomer mixture containing 0.1 to 2 mass % of an ethylenically unsaturated carboxylic acid monomer as a monomer A, 58 to 99.9 mass % of an alkyl(meth)acrylate ester having an alkyl group of 4 to 12 carbon atoms as a monomer B, 30 mass % or less of an alkyl(meth)acrylate ester having 1 to 3 carbon atoms as a monomer C, and 30 mass % or less of a monomer having an ethylenically unsaturated group other than those of the monomers A to C (the total of monomers A to D is taken as 100 mass %) as a monomer D, and the content of sulfuric acid in the acrylic copolymer is 700 ppm by mass or less. 1. An adhesive composition for medical use comprising an acrylic copolymer , a medicament having a carboxyl group , and a base ,wherein the acrylic copolymer is prepared by copolymerization of a monomer mixture containing 0.1 to 2 mass % of an ethylenically unsaturated carboxylic acid monomer as a monomer A, 58 to 99.9 mass % of an alkyl(meth)acrylate ester having an alkyl group of 4 to 12 carbon atoms as a monomer B, 30 mass % or less of an alkyl(meth)acrylate ester having an alkyl group of 1 to 3 carbon atoms as a monomer C, and 30 mass % or less of a monomer having an ethylenically unsaturated group other than those of the monomers A to C (the total of monomers A to D is taken as 100 mass %) as a monomer D, andthe content of sulfuric acid in the acrylic copolymer is 700 ppm by mass or less.2. The adhesive composition for medical use according to claim 1 , wherein the acrylic copolymer is manufactured by emulsion polymerization claim 1 , and the gel fraction thereof is 60% or higher.3. The adhesive composition for medical use according to claim 1 , wherein the medicament having a carboxyl group is an anti-inflammatory analgesic.4. A patch for medical use applying the adhesive ...

Подробнее
18-04-2013 дата публикации

COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES

Номер: US20130096093A1
Автор: HARTY Richard F.

Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. 1. An oral pharmaceutical composition comprising: a therapeutically effective amount of 5-aminosalicylic acid or a pharmaceutically-acceptable salt thereof , and a therapeutically effective amount of N-acetylcysteine or a pharmaceutically-acceptable salt thereof , together disposed in a pharmaceutically-acceptable carrier , wherein the pharmaceutical composition is formulated for oral administration to a subject.2. The composition of claim 1 , wherein the 5-aminosalicylic acid claim 1 , or a pharmaceutically-acceptable salt thereof claim 1 , is present at a dose of between 1 mg/kg to 100 mg/kg.3. The composition of claim 1 , wherein the N-acetylcysteine or a pharmaceutically-acceptable salt thereof claim 1 , is present at a dose of between 1 mg/kg to 100 mg/kg.4. The composition of claim 1 , wherein the subject is a mammal.5. The composition of claim 1 , wherein the subject is a human.6. The composition of claim 1 , further comprising at least one excipient.7. The composition of claim 1 , wherein the oral formulation is formulated into solid or liquid preparations claim 1 , selected from the group consisting of capsules claim 1 , pills claim 1 , tablets claim 1 , lozenges claim 1 , melts claim 1 , powders claim 1 , suspensions claim 1 , and emulsions.8. The composition of claim 1 , wherein the amount of the 5-amino salicylic acid and the amount of the N-acetylcysteine is effective for therapy in a subject ...

Подробнее
18-04-2013 дата публикации

PERFLUOROCARBON GEL FORMULATIONS

Номер: US20130096190A1
Принадлежит: OXYGEN BIOTHERAPEUTICS, INC.

A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses. 1. A perfluorocarbon gel composition comprising 10-90 wt % perfluorocarbon and 8-70 wt % water relative to the total weight of the gel , wherein the perfluorocarbon is perfluoro(tert-butylcyclohexane).2. (canceled)3. The perfluorocarbon gel composition of claim 1 , wherein the composition further comprises 1-5 wt % surfactants.4. The perfluorocarbon gel composition of claim 3 , wherein the surfactants include polyoxyethylene-polyoxypropylene block copolymers.5. The perfluorocarbon gel composition of claim 4 , wherein the polyoxyethylene-polyoxypropylene block copolymers include Poloxamer 105 and/or Poloxamer 188.6. The perfluorocarbon gel composition of claim 1 , wherein the composition further comprises 0.01-10 wt % Vitamin E.7. The perfluorocarbon gel composition of claim 6 , wherein the composition comprises 0.03 wt % Vitamin E.8. The perfluorocarbon gel composition of claim 1 , wherein the composition further comprises 0.02-3.20 wt % preservatives.9. The perfluorocarbon gel composition of claim 8 , wherein the preservatives include poly(diallyldimethylammonium chloride) claim 8 , poly(acrylamide-co-diallyldimethylammonium chloride) and/or ethylene diamine tetraacetic acid.10. (canceled)11. The perfluorocarbon gel composition of claim 3 , wherein the composition comprises 30-50 wt % perfluorocarbon claim 3 , 48-70 wt % water claim 3 , and 2 wt % surfactants.12. (canceled)13. (canceled)14. The perfluorocarbon gel composition of claim 8 , wherein the preservatives include 0-0.40 wt % poly(diallyldimethylammonium chloride) claim 8 , 0.01-0.80 wt % poly(acrylamide-co-diallyldimethylammonium chloride) and 0.01-2.00 wt % ethylene diamine tetraacetic acid.15. The perfluorocarbon gel composition of claim 14 , wherein the composition comprises 84-88 wt % perfluoro(tert-butylcyclohexane) claim 14 , 9-11 wt % water claim 14 , 2-3 wt % Poloxamer 105 claim 14 , 0.01- ...

Подробнее
25-04-2013 дата публикации

Anti-microbial agent from paenibacillus sp. and methods and uses thereof

Номер: US20130101559A1
Принадлежит: Best Environmental Tech Inc

The present invention provides, in part, a Paenibacillus sp. isolate, designated Paenibacillus polymyxa JB05-01-1, as well as an anti-microbial agent obtained from the bacterium or cell culture supernatant thereof. Compositions, methods and uses are also provided.

Подробнее
25-04-2013 дата публикации

DERMAL FILLER WITH LIDOCAINE

Номер: US20130102563A1
Автор: Lebreton Pierre F.
Принадлежит: ALLERGAN, INC.

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. 1. A stable dermal filler comprising:(a) a hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether, and; 'wherein the dermal filler is stable at about 25° C. for at least about 6 months after sterilization of the dermal filler.', '(b) lidocaine mixed with the crosslinked hyaluronic acid,'}2. The stable dermal filler of claim 1 , wherein the lidocaine is present at a concentration of about 0.3% by weight of the stable dermal filler.3. The stable dermal filler of claim 1 , wherein the stable dermal filler requires an extrusion force of between about 10N and about 13N when injected at a rate of about 12.5 mm/minute.4. The stable dermal filler of claim 1 , wherein the stable dermal filler has a viscosity of between about 5 Pa*s and about 450 Pa*s when measured at about 5 Hz.5. The stable dermal filler of claim 1 , wherein the stable dermal filler is a cohesive dermal filler.6. The stable dermal filler of claim 1 , wherein the stable dermal filler comprises particles of cross linked hyaluronic acid.7. The stable dermal filler of claim 1 , wherein the concentration of the hyaluronic acid in the stable dermal filler is about 20 mg/ml.8. The stable dermal filler of claim 1 , wherein the stable dermal filler has a pH of about 7.9. A dermal filler comprising:(a) a hyaluronic acid ...

Подробнее
25-04-2013 дата публикации

TOLVAPTAN SOLID DISPERSION AND ITS PREPARATION METHOD

Номер: US20130102588A1
Автор: Chen Hao, Mao Shujun, Wu Yuxia
Принадлежит: JIANGSU HENGRUI MEDICINE CO., LTD.

A tolvaptan solid dispersion and its preparation method are disclosed. The solid dispersion comprises tolvaptan and cross-linked polyvinylprrolidone at a weight ratio of 1:0.05-20, preferably 1:0.1-10, and more preferably 2:1. The solid dispersion can further comprise one or more water-soluble polymers, such as polyvinylprrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose or methylcellulose, wherein the weight ratio of tolvaptan:the crosslinked polyvinylprrolidone:the water-soluble polymers is preferably 2:1:0.1. The solid dispersion exhibits good thermodynamic stability and solubility. The pharmaceutical composition thereof has improved release rate and bioavailability. 1. A pharmaceutical solid dispersion , comprising amorphous tolvaptan or a salt thereof as an active ingredient and cross-linked polyvinylpyrrolidone.2. The pharmaceutical solid dispersion according to claim 1 , wherein the ratio claim 1 , by weight claim 1 , of the active ingredient tolvaptan or salt thereof and the cross-linked polyvinylpyrrolidone is 1:0.05-20.3. The pharmaceutical solid dispersion according to claim 2 , wherein the ratio claim 2 , by weight claim 2 , of the active ingredient and the cross-linked polyvinylpyrrolidone is 1:0.1-10.4. The pharmaceutical solid dispersion according to claim 1 , wherein the solid dispersion consists of the active ingredient and the cross-linked polyvinylpyrrolidone.5. The pharmaceutical solid dispersion according to claim 1 , wherein the solid dispersion further comprises one or more water soluble polymers.6. The pharmaceutical solid dispersion according to claim 5 , wherein the solid dispersion consists of the active ingredient claim 5 , the cross-linked polyvinylpyrrolidone and the one or more water soluble polymers.7. The pharmaceutical solid dispersion according to claim 5 , wherein the one or more water soluble polymers are selected from the group consisting of alkyl cellulose claim 5 , hydroxyalkyl cellulose and alkali metal salts thereof ...

Подробнее
02-05-2013 дата публикации

Extraction method for providing an organic certifiable stevia rebaudiana extract

Номер: US20130108718A1
Принадлежит: JUSTBIO Inc

A simple extraction method for preparing an organic certifiable stevia extract with high sweetness and optionally with antioxidant properties is provided. The extraction method involves extraction of stevia leaves that have been dried and grinded with a hot solvent generally regarded as safe (GRAS), allowing the dissolution of the sweetening compounds naturally present therein. These sweetening compounds include steviosides and rebaudioside A, which are purified from the extracts by two or more successive chromatographic purifications steps. The sweetening compounds are then eluted with an appropriate elution solvent. The simplicity and organic certification of the method provide advantages over the methods currently employed in the stevia industry.

Подробнее
02-05-2013 дата публикации

Coated effervescent tablet

Номер: US20130108745A1
Принадлежит: DELANTE HEALTH AS

A dietary tablet having a core containing a microencapsulated oil part and an effervescent agent, a coat which isolates the core from the environment and protects the core from oxidation and at least one ingredient giving taste. Suitable oils are preferably chosen from oils rich in polyunsaturated fatty acids, especially omega-3 and omega-6 fatty acids. The tablet is intended to be administered without water and to disintegrate in the oral cavity.

Подробнее
02-05-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS OF CO-CRYSTALS OF TRAMADOL AND COXIBS

Номер: US20130109659A1
Принадлежит: LABORATORIOS DEL DR. ESTEVE, S.A.

The present invention relates to oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib and processes for the preparation of these oral pharmaceutical compositions. The present invention also relates to methods of using oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib as medicaments, more particularly for the treatment of pain. 1. A pharmaceutical composition comprising a co-crystal of (rac)-tramadol.HCl-celecoxib (1:1) and at least a solubility enhancer polymer.2. The pharmaceutical composition according to wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers.3. The pharmaceutical composition according to wherein the solubility enhancer polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.4. The pharmaceutical composition according to wherein the solubility enhancer polymer is copolymer copovidone.5. The pharmaceutical composition according to wherein the content of solubility enhancer polymer used in the composition lies between 2-50 weight %.6. The pharmaceutical composition according to being in a form selected from tablet claim 1 , powder capsules claim 1 , or formulated by dry granulation claim 1 , slurries and dry roller compaction.7. A pharmaceutical composition according to in form of a tablet comprising a co-crystal of (rac)-tramadol.HCl-celecoxib (1:1) and at least a solubility enhancer polymer obtainable by a direct compression process.8. The pharmaceutical composition according to further comprising at least a surfactant polymer.9. The pharmaceutical composition according to wherein the surfactant polymer is selected from microencapsulated polisorbate 80 claim 8 , microencapsulated polyoxyl 40-hydrogenated castor oil and sodium lauryl sulphate.10. The pharmaceutical composition according to comprising at least one further pharmaceutically acceptable ...

Подробнее
02-05-2013 дата публикации

COMBINATION OF AN NSAID AND AN AMINO ACID

Номер: US20130109754A1
Принадлежит: LABORATORIOS SENOSIAIN S.A. DE C.V.

The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation. 127-. (canceled)28. A pharmaceutical combination comprising ibuprofen and L-arginine , wherein the ibuprofen/L-arginine weight ratio is between 1.6 and 5.6 , with the exception of the value approximately equal to 1.97.29. A pharmaceutical combination comprising ibuprofen and L-arginine , wherein the ibuprofen/L-arginine weight ratio is between 3.26 and 5.0.30. The combination of claim 28 , wherein the ibuprofen/L-arginine weight ratio is approximately equal to 3.26.31. The combination of claim 28 , wherein the ibuprofen/L-arginine weight ratio is approximately equal to 5.0.32. A solid pharmaceutical composition comprising the combination according to claim 28 , and pharmaceutically acceptable excipients.33. The pharmaceutical composition of claim 32 , wherein the composition is adapted for oral administration.34. The pharmaceutical composition of claim 32 , wherein the composition is in the form of a suspension claim 32 , pill claim 32 , tablet claim 32 , granulate claim 32 , powder or capsule.35. A method of treating pain claim 32 , swelling and/or fever claim 32 , comprising administering to an individual in need thereof claim 32 , the pharmaceutical composition of .36. The combination according to claim 28 , to be used as an antipyretic claim 28 , anti-inflammatory and/or analgesic agent.37. The combination according to claim 28 , to be used as an analgesic agent.38. The combination according to claim 28 , wherein ibuprofen is the enantiomer (+)S-ibuprofen.39. A pharmaceutical ...

Подробнее
09-05-2013 дата публикации

Edible wafer-type product for delivery of nutraceuticals and pharmaceuticals

Номер: US20130115266A1
Принадлежит: BestSweet Inc

A food product for carrying and delivery nutraceutical or pharmaceutical or both is provided. The food product may be an edible wafer-based outer layer and an inner layer of an edible filling comprising the nutraceutical or pharmaceutical or both.

Подробнее
09-05-2013 дата публикации

Method of making nutritional emulsions containing process- encapsulated oils

Номер: US20130115355A1
Принадлежит: ABBOTT LABORATORIES

Disclosed is a method of making nutritional emulsions, comprising: (A) heating and blending together an emulsifying agent having a melt point above about 25 C and oil having hydrophobic off-notes (e.g. non-encapsulated polyunsaturated fatty acid) in a weight ratio of at least about 1:15; (B) adding the heated blend to a fat, protein, and carbohydrate mixture comprising a maltodextrin (DE of about 10 or less), in a weight ratio of the maltodextrin to the oil having hydrophobic off-notes of at least about 1:2; and (C) homogenizing, and then cooling the combination below the melt point of the emulsifying agent to form a nutritional emulsion comprising from about 0.01% to about 5% by weight of process-encapsulated polyunsaturated fatty acid. The resulting nutritional emulsions effectively mask off-notes commonly associated with certain oils, e.g., polyunsaturated fatty acids, soy oil, beta-hydroxy-beta-methylbutyrate oils.

Подробнее
09-05-2013 дата публикации

COMPOSITIONS AND METHODS FOR TREATING ANHIDROSIS

Номер: US20130116325A1
Принадлежит:

Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses. 1. A horse feed composition or additive comprising a substantial amount of a nitric oxide enhancer for the treatment or prevention of anhidrosis in mammals.2. The horse feed composition or additive of wherein said nitric oxide enhancer is L-arginine.3. The horse feed composition or additive of wherein said nitric oxide enhancer is L-arginine in an amount of 20-35%.4. The horse feed composition or additive of wherein said nitric oxide enhancer is L-arginine in an amount of about 23%.5. The horse feed composition or additive of further comprising an antioxidant.6. The horse feed composition or additive of wherein said antioxidant is selected from the group consisting of vitamin A claim 5 , vitamin C claim 5 , vitamin E claim 5 , beta-carotene and combinations thereof.7. The horse feed composition or additive of further comprising an electrolyte.8. The horse feed composition or additive of wherein said electrolyte is selected from the group consisting of potassium claim 7 , sodium claim 7 , magnesium claim 7 , calcium claim 7 , chloride claim 7 , phosphorus claim 7 , sulfate claim 7 , carbonate claim 7 , citrate and combinations thereof.9. The horse feed composition or additive of wherein said electrolyte is a combination of sodium chloride and potassium chloride.10. The horse feed composition or additive of further comprising an omega 3 fatty acid.11. The horse feed composition or additive of wherein said omega 3 fatty acid is selected from the group consisting of α-linoleic acid claim 10 , eicosapentaenoic acid claim 10 , docosahexaenoic acid claim 10 , and combinations thereof.12. The horse feed composition or additive of further comprising L-tyrosine.13. The horse feed composition or additive of that comprises about 30.5% potassium chloride claim 1 , about 24.5% sodium chloride claim 1 , about 23% L-arginine claim 1 , about 12.2% vitamin C claim 1 , ...

Подробнее
09-05-2013 дата публикации

Thermogelling Anaesthetic Compositions

Номер: US20130116328A1
Принадлежит: PHARMANEST AB

The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics. 1. A thermogelling stabilized pharmaceutical composition of one or more local anaesthetics with a pH of at least about the pKof said local anaesthetics comprising;(a) the base form of one or more local anaesthetics of the amide type ATC code N01BB;(b) a polyoxyethylene castor oil in an amount of between 10 to 30% by weight; and(c) one or more surfactants in an amount of at least 15% by weight to provide the composition with thermogelling properties.2. The pharmaceutical composition according to further comprising a solubilizer in an amount of between 0 to 10% by weight claim 1 , preferably in an amount of between 1 to 5% by weight.3. The pharmaceutical composition according to wherein the one or more local anaesthetics are present in an amount of between 1 to 20% by weight.4. The pharmaceutical composition according to claim 1 , wherein the local anaesthetic of the amide type is selected from the group consisting of lidocaine claim 1 , prilocaine claim 1 , mepivacaine claim 1 , ropivacaine claim 1 , bupivacaine claim 1 , and levobupivacaine.5. The pharmaceutical composition according to claim 4 , comprising the base form of lidocaine present in an amount of 1 to 7% by weight.6. The pharmaceutical composition according to wherein the polyoxyethylene castor oil is present in an amount of between 10 and 30% by weight.7. The pharmaceutical composition according to claim 1 , wherein the one or more surfactants are non-ionic block copolymers of the poly(oxyethylene) and poly(oxypropylene) type and present in an amount 15 to 30% by weight.8. The pharmaceutical composition according to claim 6 , wherein the block copolymers comprise a higher molecular weight poloxamer and a ...

Подробнее
16-05-2013 дата публикации

Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents

Номер: US20130121929A1
Принадлежит: AMAG PHARMACEUTICALS, INC.

Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods. 1. A autoclaved unit dose of an iron oxide complex comprising:particles of a superparamagnetic iron oxide coated with a carboxymethylated reduced dextran having between about 1100 micromoles and about 1500 micromoles carboxyl per gram of carboxymethylated reduced dextran, wherein the reduced dextran has an average molecular weight of about 10 kDa, and wherein the particles have a diameter between about 10 nm and about 50 nm, and 'wherein the autoclaved unit dose has about 500 mg to about 600 mg of iron.', 'a biocompatible liquid;'}2. The autoclaved unit dose of claim 1 , wherein the unit dose has less than about 0.1% free iron concentration as determined by atomic absorption spectroscopy on a sample of the unit dose filtered through a 30K molecular weight cutoff micropartition membrane filter.3. The autoclaved unit dose of claim 1 , wherein the particles have a magnetic susceptibility of greater than 20 claim 1 ,000×10cgs.4. A pharmacological composition comprising:an autoclaved colloid comprising particles of a superparamagnetic iron oxide coated with a carboxymethylated reduced dextran, the reduced dextran having an average molecular weight of about 10 kDa; and a biocompatible liquid, ...

Подробнее
16-05-2013 дата публикации

THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN

Номер: US20130121987A1
Автор: Taylor Harold Victor
Принадлежит: Merz Pharma GmbH & Co. KGaA

The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from , the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin. 1Clostridium botulinum. A pharmaceutical composition consisting essentially of a botulinum neurotoxin from of type A , B , C1 , D , E , F or G or a mixture of two or more botulinum neurotoxins , wherein the neurotoxin or mixture of neurotoxins is free of the complexing proteins which naturally form complexes with botulinum neurotoxins , a non-proteinaceous stabilizing agent selected from hyaluronic acid , polyvinylpyrrolidone and polyethyleneglycol , and a sodium acetate pH buffer , wherein the composition is freeze-dried.2. The pharmaceutical composition of claim 1 , wherein the botulinum neurotoxin is modified chemically or modified by genetic manipulation claim 1 , or is a mixture thereof.3. The pharmaceutical composition of claim 1 , wherein the non-proteinaceous stabilizing agent is hyaluronic acid.4. The pharmaceutical composition of claim 1 , wherein the pH of the composition prior to freeze-drying is in a range of about 4.5 to about 5.5.5. The pharmaceutical composition of claim 1 , wherein the pH of the composition after reconstitution is a range of about 6.5 to about 7.5.6. The pharmaceutical composition of claim 1 , for administration to an animal claim 1 , including a human claim 1 , in an amount effective for the treatment of a condition for which botulinum neurotoxin therapy or treatment is indicated.7. The pharmaceutical composition of claim 6 , wherein the condition for which botulinum neurotoxin therapy or treatment is indicated is selected from cosmetic conditions claim 6 , blepharospasm claim 6 , hemifacial spasms claim ...

Подробнее
16-05-2013 дата публикации

DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS

Номер: US20130123210A1
Принадлежит: ALLERGAN, INC.

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins. 1. An injectable dermal filler comprising:hyaluronic acid; and 'wherein a degree of conjugation is between about 3 mol % and about 40 mol %.', 'a vitamin C derivative covalently conjugated to the hyaluronic acid;'}2. The dermal filler of wherein the hylauronic acid is crosslinked with Star-PEG epoxide.3. The dermal filler of wherein the hyaluronic acid is crosslinked with Star-PEG amine.4. The dermal filler of wherein the hyaluronic acid is crosslinked with BDDE.5. The dermal filler of wherein and the degree of conjugation is between about 3 mol % and about 15 mol %.6. The dermal filler of wherein vitamin C derivative is AA2G.7. The dermal filler of wherein the vitamin C derivative is Vitagen.8. The dermal filler of wherein the vitamin C derivative is AA2P.9. The dermal filler of used in treating a skin defect wherein claim 1 , when introduced into the skin of a human being claim 1 , releases ascorbic acid into the human being for at least about 1 month and up to about 20 months.10. An injectable dermal filler comprising:hyaluronic acid crosslinked with Star PEG amine and having a degree of conjugation of between about 3 mol % and about 40 mol %; and 'wherein the dermal filler, when introduced into the skin of a human being, releases ascorbic acid into the human being for at least about 1 months and up to about 20 months.', 'AA2P covalently conjugated to the hyaluronic acid'}11. A method of making a dermal filler comprising the steps of:providing hyaluronic acid;reacting a crosslinking agent with a Vitamin C derivative;adding the reacted crosslinking agent and Vitamin C derivative to the hyaluronic acid to form a crosslinked hyaluronic acid composition including covalently conjugated Vitamin C; andhomogenizing and neutralizing the crosslinked hyaluronic acid composition to obtain an injectable gel having a conjugation degree of between about 3 mol % and about 40 mol ...

Подробнее
16-05-2013 дата публикации

MEDICINAL AGENT FOR PREVENTION AND/OR TREATMENT OF HEPATOCELLULAR CARCINOMA

Номер: US20130123363A1
Принадлежит: KOWA CO., LTD.

The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these. 1. A pharmaceutical agent suitable for prevention , treatment , or both prevention and treatment of hepatocellular carcinoma , the agent comprising:an acyclic retinoid, an acyclic retinoid salt thereof, an acyclic retinoid solvate of any of these, or an acyclic retinoid salt solvate anda branched-chain amino acid, a branched-chain amino acid salt, a branched-chain amino acid solvate, or a branched-chain amino acid salt solvate.2. The agent of claim 1 , wherein the acyclic retinoid is peretinoin.3. The agent of claim 1 , wherein the branched-chain amino acid comprises: a combination of isoleucine claim 1 , leucine claim 1 , and valine.4. The agent of claim 1 , wherein the agent is capable of inhibiting recurrence of hepatocellular carcinoma after treatment therewith.5. The agent of claim 1 , wherein the agent is capable of treating hepatocellular carcinoma caused by a hepatitis virus or non-alcoholic steatohepatitis.6. The agent of claim 5 , wherein the agent is capable of treating hepatitis C virus or hepatitis B virus.7. The agent of claim 1 , wherein the agent is a single preparation.8. A kit comprising: the agent of .9. A pharmaceutical agent suitable for prevention claim 1 , treatment or both prevention and treatment of hepatocellular carcinoma claim 1 , the agent comprising:an acyclic retinoid, an acyclic retinoid salt, an acyclic retinoid solvate, or an acyclic retinoid salt solvate,wherein the agent is suitable for co-administering with a branched-chain amino acid, a branched-chain amino acid salt, a branched-chain amino acid solvate, or a branched amino acid salt ...

Подробнее